About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase II clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.
This press release may contain "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or to VIA's future financial performance
and involve known and unknown risks, uncertainties and other factors that
may cause VIA's actual results, levels of activity, performance or
achievements to be expressed or implied by these forward-looking
statements. In some cases, you can identify forward-looking statements by
the use of words such as "may," "could," "expect," "intend," "plan,"
"seek," "anticipate," "believe," "estimate," "predict," "potential,"
"continue" or the negative of these terms or other comparable terminology.
You should not place undue reliance on forward-looking statements
|SOURCE VIA Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved